Lumera Adds Two Biotech Luminaries to its Scientific Advisory Board; Scientists to Provide Strategic Direction for Bioscience Business Unit

"The addition of these two noted scientists to our ScientificAdvisory Board is a tremendous gain for our Bioscience Business Unit.Their insight will be invaluable in moving forward with our strategicdirection," said Dr. Timothy Londergan, Lumera's director, BioscienceBusiness Unit.

Leroy Hood, M.D., Ph.D. is recognized as one of the world'sleading scientists in molecular biotechnology and genomics, holdingnumerous patents and awards for his scientific breakthroughs. Dr. Hoodearned an M.D. from Johns Hopkins University in 1964 and a Ph.D. inbiochemistry from the California Institute of Technology in 1968.Since then, his research has focused on the study of molecularimmunology and biotechnology. He has published more than 600peer-reviewed papers and co-authored textbooks in biochemistry,immunology, molecular biology and genetics.

His professional career began at Caltech, where he and colleaguespioneered four instruments, the DNA and protein synthesizers andsequencers that constitute the technological foundation forcontemporary molecular biology. One of the instruments hasrevolutionized genomics by allowing the rapid automated sequencing ofDNA. Dr. Hood also was one of the first advocates and is a key playerin the Human Genome Project -- the quest to decipher the sequence ofhuman DNA.

In 2000, Dr. Hood founded the Institute for Systems Biology inSeattle, Washington, to pioneer systems approaches to biology andmedicine. He is president and director of this organization andcontinues with his interest in biology, medicine, technologydevelopment, and computational biology.

Dr. Hood has played a role in founding several biotechnologycompanies, including Amgen, Applied Biosystems, Systemix, Darwin,Rosetta, and MacroGenics. His numerous awards include the Kyoto Prizefor Advanced Technology (2002).

Joshua LaBaer, M.D., Ph.D., is the founder and Director of theInstitute of Proteomics at Harvard Medical School, and is a boardcertified oncologist in Massachusetts. He attended the University ofCalifornia at Berkeley as an undergraduate and completed medicalschool and graduate school at the University of California, SanFrancisco, where he studied steroid regulation of DNA transcriptionand protein-DNA interactions.

He completed his clinical studies at the Brigham and Women'sHospital and a clinical fellowship in Oncology at the Dana-FarberCancer Institute in Boston. He also pursued research interests at theMassachusetts General Hospital in Boston in the areas of breastcancer, mammalian cell cycle regulation and cell cycle checkpointgenes.

Dr. LaBaer is the inventor of a new protein array technologycalled Nucleic Acid Programmable Protein Arrays (NAPPA). The NAPPAtechnology, first published in the July 2004 issue of the journalScience, provides a simple, cost-effective way to produce, as a singleelement of a microarray, freshly synthesized protein corresponding toany gene of known sequence.

He currently holds an academic appointment through the Departmentof Biological Chemistry and Molecular Pharmacology at Harvard MedicalSchool. The author of numerous publications, Dr. LaBaer is also anassociate editor of the Journal of Proteome Research, a member of theScientific Advisory Committee for the Proteome Society and a foundingmember of the Human Proteome Organization.

About Lumera

Lumera is a leader in the emerging field of nanotechnology. Thecompany designs proprietary molecular structures and polymer compoundsfor the bioscience and communications/computing industries, both ofwhich represent large market opportunities. The company also hasdeveloped proprietary processes for fabricating such devices. For moreinformation, please visit www.lumera.com.

About the Institute for Systems Biology

The Institute for Systems Biology (ISB) is an internationallyrenowned non-profit research institute dedicated to the study andapplication of systems biology. ISB's goal is to unravel the mysteriesof human biology and identify strategies for predicting and preventingdiseases such as cancer, diabetes and AIDS. The driving force behindthe innovative systems biology approach is the integration of biology,computation and technology. This approach allows scientists to analyzeall of the elements in a system rather than one gene or protein at atime. For more information about the ISB, visit www.systemsbiology.org

Certain statements contained in this release are forward-lookingstatements that involve a number of risks and uncertainties. Factorsthat could cause actual results to differ materially from thoseprojected in the company's forward-looking statements include thefollowing: market acceptance of our technologies and products; ourability to obtain financing; our financial and technical resourcesrelative to those of our competitors; our ability to keep up withrapid technological change; government regulation of our technologies;our ability to enforce our intellectual property rights and protectour proprietary technologies; the ability to obtain additionalcontract awards and to develop partnership opportunities; the timingof commercial product launches; the ability to achieve key technicalmilestones in key products; and other risk factors identified fromtime to time in the company's SEC reports, including its Annual Reporton Form 10-K, and its Quarterly Reports on Form 10-Q.